Medical Advocates
Pegylated Interferon alfa-2a (Pegasys)
  Journal Citations
General Reports
 Efficacy
 Pharmacoeconomics




 		  
Peg Inf alfa 2a HBV Main Page Main New/Newsworthy  Home Page
Last Update:  March 17, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment
of dual chronic infection with hepatitis B and C viruses.
 Yu ML, Lee CM, Chuang WL,  et al
J Infect Dis. 2010 Jul 1;202(1):86-92.
 Abstract

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive
chronic hepatitis B using decline of HBV DNA during treatment.
 Hansen BE, Buster EH, Steyerberg EW, et al
J Med Virol. 2010 Jul;82(7):1135-42.
 Abstract

Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.
 Keating GM.
Drugs. 2009;69(18):2633-60
 Abstract

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B:
a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, et al
Health Technol Assess. 2006 Aug;10(28)
 Abstract

FULL-TEXT ARTICLE
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more
sensitive to interferon than genotype D.
Erhardt A, Blondin D, Hauck K, et al
Gut. 2005 Jul;54(7):1009-13
Paper
Efficacy
 
     Journal Papers, Abstracts, and Commentaries
 
 
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir.
 Takkenberg RB, Terpstra V, Zaaijer HL,  et al
 J Gastroenterol Hepatol. 2011 May 9.
Abstract

FULL-TEXT PDF ARTICLE
Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg
clearance by treated with pegylated interferon alpha-2a for less than 1 year:
a short report.
 Yang J, Zhao LS. 
Virol J. 2009 Jul 8;6(1):97.
Paper

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in
HBeAg-negative chronic hepatitis B.
 Brunetto MR, Moriconi F, Bonino F, et al 
Hepatology. 2009 Apr;49(4):1141-50.
 Abstract

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B
 and C Viruses.
 Liu CJ, Chuang WL, Lee CM, et al
 Gastroenterology. 2008 Oct 29
 Abstract
 
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with
chronic hepatitis C.
 Njouom R, Sartre MT, Timba I,  et al  
J Med Virol. 2008 Dec;80(12):2079-85.
 Abstract
 
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs
chronic hepatitis C treated with peginterferon alpha-2a.
 Marcellin P, Lau GK, Zeuzem S, et al
 Liver Int. 2008 Apr;28(4):477-85.
 Abstract
 
A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e
Antigen-Negative Chronic Hepatitis B.
 Gish RG, Lau DT, Schmid P, Perrillo R.
Am J Gastroenterol. 2007 Jul 27;
Abstract

A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during
pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P, Civitano L, Bizzarri R, et al
Antivir Ther. 2006;11(2):197-212.
 Abstract

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis
B.Lau GK, Piratvisuth T, Luo KX,
N Engl J Med. 2005 Jun 30;352(26):2682-95
 Abstract
 
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients
with HBeAg-negative chronic hepatitis B.
Marcellin P, Lau GK, Bonino F, et al
N Engl J Med. 2004 Sep 16;351(12):1206-17.
Abstract
 
Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
Cooksley WG.
Semin Liver Dis. 2004;24 Suppl 1:45-53.
 Abstract
 
Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine.
Hasan F, al-Khaldi J, Asker H,et al
 Hepatogastroenterology. 2003 Nov-Dec;50(54):2040-2
 Abstract
 
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-
positive chronic hepatitis B.
Cooksley WG, Piratvisuth T, Lee SD, et al
J Viral Hepat. 2003 Jul;10(4):298-305.
 Abstract
 
Twenty-four weeks administration of interferon-alpha for chronic hepatitis B
Honda Y, Fujiyama S, Chikazawa H.
Nippon Shokakibyo Gakkai Zasshi. 2002 Oct;99(10):1213-9.
 Abstract
Pharmacoeconomics
 

     Journal Papers, Abstracts, and Commentaries

 
HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to
lamivudine in Taiwan.
 Veenstra DL, Sullivan SD, Lai MY, et al
Value Health. 2008 Mar-Apr;11(2):131-8.
 Abstract

Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with
hepatitis B e antigen positive chronic hepatitis B in Taiwan.
 Sullivan SD, Veenstra DL, Chen PJ, et al 
 J Gastroenterol Hepatol. 2007 Sep;22(9):1494-9.
Abstract

Peg Inf alfa 2a HBV Main Page Main New/Newsworthy  Home Page

Pegylated Interferon Alfa-2a
HBV Journal Citations